AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

NASDAQ:CLLSCellectis Stock Price, Forecast & News

$18.47
+0.37 (+2.04 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.95
Now: $18.47
$19.00
50-Day Range
$9.09
MA: $14.56
$21.02
52-Week Range
$7.32
Now: $18.47
$21.97
Volume260,774 shs
Average Volume160,236 shs
Market Capitalization$784.35 million
P/E RatioN/A
Dividend YieldN/A
Beta2.15
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.
Read More
Cellectis logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.99 million
Book Value$8.73 per share

Profitability

Net Income$-102,090,000.00

Miscellaneous

Employees161
Market Cap$784.35 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

How has Cellectis' stock been impacted by COVID-19 (Coronavirus)?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLLS shares have increased by 61.6% and is now trading at $18.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cellectis?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cellectis.

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cellectis.

How were Cellectis' earnings last quarter?

Cellectis SA (NASDAQ:CLLS) released its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.59) by $1.06. The biotechnology company earned $51.91 million during the quarter, compared to the consensus estimate of $21.07 million. Cellectis had a negative return on equity of 17.60% and a negative net margin of 93.27%. View Cellectis' earnings history.

What price target have analysts set for CLLS?

7 equities research analysts have issued 1-year price objectives for Cellectis' stock. Their forecasts range from $11.00 to $73.00. On average, they anticipate Cellectis' share price to reach $32.33 in the next year. This suggests a possible upside of 75.1% from the stock's current price. View analysts' price targets for Cellectis.

Has Cellectis been receiving favorable news coverage?

Media headlines about CLLS stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cellectis earned a daily sentiment score of -3.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the company's share price in the next several days. View the latest news aboutCellectis.

Are investors shorting Cellectis?

Cellectis saw a increase in short interest in May. As of May 15th, there was short interest totaling 356,700 shares, an increase of 34.4% from the April 30th total of 265,400 shares. Based on an average trading volume of 147,800 shares, the short-interest ratio is presently 2.4 days. Currently, 0.8% of the shares of the company are sold short. View Cellectis' Current Options Chain.

Who are some of Cellectis' key competitors?

What other stocks do shareholders of Cellectis own?

Who are Cellectis' key executives?

Cellectis' management team includes the following people:
  • Dr. André Choulika, Co-Founder, Chairman & CEO (Age 54)
  • Dr. David J. D. Sourdive, Co-Founder, Deputy CEO, Exec. VP of Technical Operations & Director (Age 52)
  • Mr. Eric Dutang, Chief Financial Officer (Age 45)
  • Ms. Elsy Boglioli, Chief Operating Officer (Age 37)
  • Mr. Jean Charles Epinat, Chief Technological Officer

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital International Investors (3.31%), Nikko Asset Management Americas Inc. (3.04%), Sumitomo Mitsui Trust Holdings Inc. (3.04%), Nikko Asset Management Americas Inc. (3.04%), Morgan Stanley (1.70%) and Morgan Stanley (1.70%).

Which institutional investors are selling Cellectis stock?

CLLS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vident Investment Advisory LLC, Wells Fargo & Company MN, WS Management Lllp, Victory Capital Management Inc., and Victory Capital Management Inc..

Which institutional investors are buying Cellectis stock?

CLLS stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, ING Groep NV, JPMorgan Chase & Co., Ikarian Capital LLC, Advisor Group Holdings Inc., Trexquant Investment LP, Nikko Asset Management Americas Inc., and Nikko Asset Management Americas Inc..

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $18.47.

How big of a company is Cellectis?

Cellectis has a market capitalization of $784.35 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe.

What is Cellectis' official website?

The official website for Cellectis is www.cellectis.com.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.